WuXi XDC Cayman stock
2268.HKHKSEWuXi XDC Cayman Inc, HealthcareISIN KYG9808A1058
73Score 73 out of 100, Strong
Price and trend
75 / 100
Price history
+6.8% in one yearThe chart shows daily closes over 3 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 14% above it.
Since September 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 52).
The price is 14% below its 52-week high. Largest decline in 3 years: 61% (December 2023 to February 2024).
Chart figures for advanced users
- SMA 50$9.58
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$8.03
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)52
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$5.84
- The lowest closing price of the last twelve months.
- Resistance$10.73
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- WuXi XDC Cayman Inc belongs to the Medical (Diagnostics & Research) industry (China) and, with a market value of $11.63B, is number 20 of 37 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $891.1M (up 46.7% year on year) and earnings of $221.94M (up 38.4%).
- MEQIRI Score 73 out of 100 (Strong): rank 92 of 714 in Healthcare, median 53.
Show more
- The P/E is 54.5 (Healthcare sector median 32.6, own median of recent years 44.7).
- Our model puts fair value at $8.79, with the price 4% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 109.1% a year since 2021, Healthcare sector median 12%.Growth 88
- Earnings per share growingUp 122.6% a year since 2020.Growth 88
- High return on capitalReturn on invested capital 37.8% in fiscal 2025, Healthcare sector median 9.1%.Profitability 82
Weaknesses
- Richly valuedP/E 54.5, Healthcare sector median 32.6, own median 44.7.Valuation 36
- Margin may fall backOperating margin 27.3%, average of the prior years 17.2%, which ranged from −6.6% to 23.4%. After peaks like this, the margin was more than a quarter lower two years later in 44 of 100 cases, against 24 of 100 for other companies with high margins.
- Volatile share priceVolatility 55% a year over the last 12 months.
Its standout strengths are growth and profitability, while valuation holds the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk not measured
How well MEQIRI warnsFor stocks from Japan, China, Hong Kong, Taiwan, Korea, Canada, India and Brazil we only show crash risk once a separate backtest shows that it warns as well there as in the US and Europe.
Valuation
Valuation signal
Fairly valuedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $6.28 and expensive above $14.65 (uncertainty high, based on the price swings of the past year).
The two parts of the fair value come to $12.08 (cash-flow model) and $5.50 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 8.4%. At 9.4% the fair value would be $7.79, at 7.4% it would be $10.19.
Valuation metrics
Half from the cash-flow model, half from earnings times the sector P/E (32.6).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Jun 2026, revenue rose 35.5% on the twelve months before. Revenue has grown strongly since 2021, at around 109% per year. From 2021 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 36%, operating 27%, net 25%. From 2021 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Debt & balance sheet
latest quarterThe balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 29 Mar 2027in 137 days
- Last reported
- 24 Aug 2026EPS reported 0.59 (expected 0.68)below expectations
Analyst estimates
Earnings estimates have barely changed since 24 Oct 2026.
- Earnings per share
- 1.79+0.8%
- Revenue
- $1.44B+0.4%
- Earnings per share
- 2.55+0.5%
- Revenue
- $1.94B+0.5%
MEQIRI has stored the estimates since 24 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
What happened at WuXi XDC Cayman
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 73
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Diagnostics & Research)
The next larger and next smaller companies by market value
- Eurofins ScientificERF.PA $17B61
- Charles River Laboratories InternationalCRL $16.42B55
- ICON PublicICLR $14.96B62
- bioMérieuxBIM.PA $12.07B70
- QiagenQGEN $10.39B76
- RadNetRDNT $6.14B44
- GRAILGRAL $5.65B43
- BillionToOneBLLN $5.27B64
ETFs that hold WuXi XDC Cayman
Held by 40 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Healthcare Innovation UCITS ETF2B78 | 0.35% | 0.40% | €1.49B |
| Deka MSCI China ex A Shares UCITS ETFEL46 | 0.20% | 0.65% | €74.12M |
| Xtrackers MSCI China UCITS ETF 1CXCS6 | 0.15% | 0.65% | €1.51B |
Show 5 more
| Franklin FTSE China UCITS ETFFLXC | 0.14% | 0.19% | €1.3B |
| UBS MSCI China Universal UCITS ETF USD disUETC | 0.14% | 0.30% | €134.65M |
| Xtrackers MSCI Emerging Markets ESG UCITS ETF 1CXZEM | 0.07% | 0.25% | €1.15B |
| State Street SPDR MSCI EM Asia UCITS ETF Accum USDSPYA | 0.04% | 0.55% | €1.3B |
| Vanguard FTSE Emerging Markets UCITS ETF (USD) AccumulatingVFEA | 0.04% | 0.17% | €5.24B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 11 Nov 2026 ($1 = HK$7.8456, $1 = CN¥6.6707)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 7 Aug 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.